Currently searching for a PhD position

Please note that this is a real resume, and I’m looking for a PhD position at the moment. I made this resume following a recommendation that it would effectively showcase my qualifications to prospective supervisors.

I hold a master’s degree in Biochemistry and Molecular Biology from Fujian Medical University and have 5 years of experience in the field of precision medicine for cancer, specialized in NGS bioinformatics analysis and statistical work. I have participated in several research projects and involved in four publications\(^{1-4}\) to date. I am seeking a PhD Position in the field of Molecular Biology or Bioinformatics related to cancer or other interesting topic.

If you are interested in my background and skills, please feel free to contact me.

Sanming University

B.S. in biotechnology

Sanming, China

2009

Thesis: Analysis of planting resources of Anoectochilus based on ITS sequence

Fujian Medical University

M.S. in Biochemistry and Molecular Biology

Fuzhou, China

2013

Thesis: The interaction between the hepatitis B virus spliced protein HBSP and the hepatic cell UXT and their effects on the NF-κB pathway.

Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences

Ph.D. candidate in Biochemistry and Molecular Biology

Shanghai, China

2016

• Research direction: Mechanism analysis of post-transcriptional modification process, including RNA splicing and protein ubiquitination modification.
• Performed molecular experiments to explore how QKI-5 protein regulates the ADD3 gene alternative splicing in cancer\(^{2}\).
• Explore the role of SPSB1-mediated ubiquitination in the initiation and progression of tumorigenesis.

Medical data analysis

OrigiMed Co., Ltd

Shanghai, China

2018 - 2023

• Performed data visualization for the article’s results, profiling the genomic features and their therapeutic potential in small cell lung cancer\(^{4}\).
• Conducted an independent analysis of clinical NGS data from gastric cancer patients, collaborated with others to draft and refine the manuscript, and submit it for publication to investigate therapeutic implications for Chinese patients\(^{3}\).
• In the project focused on investigating somatic alterations in solid tumors within the Chinese population to decode their molecular profiles, I served as the main support. My primary responsibilities encompassed data analysis, submission, and assistance in the drafting and revision of the manuscript\(^{1}\).
• Assisted in a systematic pan-cancer study of structural variants in oncogenes\(^{5}\).
• Collaborated with an AI engineer who developed deep learning algorithms, contributing to the design of an AI model for predicting the presence of gene variants in tumor samples to aid in pharmaceutical recruitment\(^{6}\).
• Curated findings or conclusions of precision therapy (targeted/immunotherapy) from literature or guidelines (e.g., NCCN) into an actionable in-house knowledge database.
• Generated real-world data reports, which included gene prevalence, gene variant-related clinical prognosis, and gene-related clinical insights, to support medical or biological professionals.
• Analyzed label-free quantitative proteomics data.

Introduction to R Language for Beginners.

Instructor of R and Data Analysis Training Courses in Department of Medical Knowledge Management at OrigiMed Co., Ltd

Shanghai, China

2020

Medical Molecular Biology Experiments Course.

Teaching assistant of Medical Molecular Biology Experiments Course at Fujian Medical University

Fuzhou, China

2014 - 2016

1. Landscape of Somatic Alterations in Large-Scale Solid Tumors from an Asian Population.

Nat Commun 13, no. 1 (Jul 23 2022): 4264. https://dx.doi.org/10.1038/s41467-022-31780-9.

Shanghai, China

2022

Wu, L., H. Yao, H. Chen, A. Wang, K. Guo, W. Gou, Y. Yu, X. Li, M. Yao, S. Yuan, F. Pang, J. Hu, L. Chen, W. Liu, J. Yao, S. Zhang, X. Dong, W. Wang, J. Hu, Q. Ling, S. Ding, Y. Wei, Q. Li, W. Cao, S. Wang, Y. Di, F. Feng, G. Zhao, J. Zhang, L. Huang, J. Xu, W. Yan, Z. Tong, D. Jiang, T. Ji, Q. Li, L. Xu, H. He, L. Shang, J. Liu, K. Wang, D. Wu, J. Shen, Y. Liu, T. Zhang, C. Liang, Y. Wang, Y. Shang, J. Guo, G. Liang, S. Xu, J. Liu, K. Wang, and M. Wang.

2. Qki-5 Regulates the Alternative Splicing of Cytoskeletal Gene Add3 in Lung Cancer.

J Mol Cell Biol 13, no. 5 (Aug 18 2021): 347-60. https://dx.doi.org/10.1093/jmcb/mjaa063.

Shanghai, China

2021

Wang, J. Z., X. Fu, Z. Fang, H. Liu, F. Y. Zong, H. Zhu, Y. F. Yu, X. Y. Zhang, S. F. Wang, Y. Huang, and J. Hui.

3. Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.

Oncologist 26, no. 5 (May 2021): e756-e68. https://dx.doi.org/10.1002/onco.13695.

Shanghai, China

2021

Yu, P., Y. Wang, Y. Yu, A. Wang, L. Huang, Y. Zhang, W. Liu, H. Wu, M. Yao, Y. A. Du, and X. Cheng.

4. Comprehensive Genomic Profiling of Small Cell Lung Cancer in Chinese Patients and the Implications for Therapeutic Potential.

Cancer Med 8, no. 9 (Aug 2019): 4338-47. https://dx.doi.org/10.1002/cam4.2199.

Shanghai, China

2019

Hu, J., Y. Wang, Y. Zhang, Y. Yu, H. Chen, K. Liu, M. Yao, K. Wang, W. Gu, and T. Shou.

5. Systematic analysis of actionable gene fusions by NGS-based in pancancer for precision oncology in China.

Meeting Abstract, Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) e15072-e15072. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e15072

Shanghai, China

2022

S Yuan, R Li, K Wang, X Shi, Y Yu, F Liu, A Wang, L Mei, H Chen

6. Use of an Artificial Intelligence (Ai) -Based Pre-Screening Tool for Patients with Bladder Cancer with Fibroblast Growth Factor Receptor (Fgfr) Alteration.

Meeting Abstract, Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e13580-e13580. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e13580

Shanghai, China

2023

Shi, G. B., Y. F. Yu, A. D. Wang, Y. Liu, and X. L. Shi.